Matinas biopharma announces positive data in the ongoing enact trial of mat2203 (oral amphotericin b) for the treatment of cryptococcal meningitis, exceeding the prespecified primary endpoint threshold

– step-down therapy with mat2203 achieved effective clearance of fungal organisms; mean early fungicidal activity (efa) was 0.38, exceeding the prespecified primary endpoint threshold target of >0.20 –

MTNB Ratings Summary

MTNB Quant Ranking